{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:07:07Z","timestamp":1791403627883,"version":"4.3.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1007\/s00213-002-1095-1","type":"journal-article","created":{"date-parts":[[2003,3,5]],"date-time":"2003-03-05T19:14:55Z","timestamp":1046891695000},"page":"223-224","source":"Crossref","is-referenced-by-count":27,"title":["Anxiogenic, not psychotogenic, properties of the partial inverse benzodiazepine receptor agonist FG 7142 in man"],"prefix":"10.1007","volume":"162","author":[{"given":"R.","family":"Horowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dorow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,5,1]]},"reference":[{"key":"1095_CR1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s002130100854","volume":"158","author":"B Angrist","year":"2001","unstructured":"Angrist B, Rotrosen J, Gershon S (2001) Commentary on: \u201cDifferential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.\u201d Psychopharmacology 158:219\u2013221","journal-title":"Psychopharmacology"},{"key":"1095_CR2","first-page":"237","volume-title":"CNS receptors \u2014 from molecular pharmacology to behaviour","author":"C Braestrup","year":"1983","unstructured":"Braestrup C, Nielsen M, Honor\u00e9 T (1983) Benzodiazepine receptor ligands with positive and negative efficacy. In: Mandel P, DeFeudis FV (eds) CNS receptors \u2014 from molecular pharmacology to behaviour. Raven Press, New York, pp 237\u2013245"},{"key":"1095_CR3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1523\/JNEUROSCI.05-02-00477.1985","volume":"5","author":"JN Crawley","year":"1985","unstructured":"Crawley JN, Ninan PT, Pickar D, Chrousos GP, Linnoila M, Skolnick P, Paul SM (1985) Neuropharmacological antagonism of the beta-carboline-induced \u201canxiety\u201d response in rhesus monkeys. J Neurosci 5:477\u2013485","journal-title":"J Neurosci"},{"key":"1095_CR4","unstructured":"Dorow R, Horowski R (1983) A ligand to benzodiazepine receptors induces severe anxiety in man. Abstracts, Third European Winter Conference on Brain Research, Les Arcs, France"},{"key":"1095_CR5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(83)90076-4","volume":"II","author":"R Dorow","year":"1983","unstructured":"Dorow R, Horowski R, Paschelke G, Amin M (1983) Severe anxiety induced by FG 1742, a\u03b2-carboline ligand for benzodiazepine receptors. Lancet II:98\u201399","journal-title":"Lancet"},{"key":"1095_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0361-9230(87)90100-6","volume":"19","author":"R Dorow","year":"1987","unstructured":"Dorow R, Duka T, H\u00f6ller L, Sauerbrey N (1987) Clinical perspectives of \u03b2-carbolines from first studies in humans. Brain Res Bull 19:319\u2013326","journal-title":"Brain Res Bull"},{"key":"1095_CR7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/978-3-642-73288-1_18","volume-title":"Psychopharmacology series 6: benzodiazepine receptor ligands, memory and information processing","author":"T Duka","year":"1988","unstructured":"Duka T, Edelmann V, Sch\u00fctt B, Dorow R (1988) \u03b2-Carbolines as tools in memory research. In: Hindmarch I, Ott H (eds) Psychopharmacology series 6: benzodiazepine receptor ligands, memory and information processing. Springer, Berlin Heidelberg New York, pp 246\u2013260"},{"key":"1095_CR8","first-page":"303","volume":"126","author":"R Horowki","year":"1984","unstructured":"Horowki R (1984) \u00dcber Angst. Munch Med Wochenschr 126:303\u2013304","journal-title":"\u00dcber Angst. Munch Med Wochenschr"},{"key":"1095_CR9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF00498510","volume":"321","author":"P Polc","year":"1982","unstructured":"Polc P, Bonetti EP, Schaffner R, Haefely W (1982) A three-state model of the benzodiazepine receptor model explains the interactions between the benzodiazepine antagonist Ro 15\u20131788, benzodiazepine tranquilizers, \u03b2-carbolines and phenobarbitone. Naunyn Schmiedebergs Arch Pharmacol 321:260\u2013264","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1095_CR10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/978-3-642-73288-1_17","volume-title":"Psychopharmacology series 6: benzodiazepine receptor ligands, memory and information processing","author":"M Sarter","year":"1988","unstructured":"Sarter M, Stephens DN (1988) \u03b2-Carbolines as tools in memory research: animal data and speculations. In: Hindmarch I, Ott H (eds) Psychopharmacology series 6: benzodiazepine receptor ligands, memory and information processing. Springer, Berlin Heidelberg New York, pp 230\u2013245"},{"key":"1095_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130100756","volume":"156","author":"M Sarter","year":"2001","unstructured":"Sarter M, Bruno JP, Berntson GG (2001) Psychotogenic properties of benzodiazepine receptor inverse agonists. Psychopharmacology 156:1\u201313","journal-title":"Psychopharmacology"},{"key":"1095_CR12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/BF00212837","volume":"94","author":"M-H Thi\u00e8bot","year":"1988","unstructured":"Thi\u00e8bot M-H, Soubri\u00e9 P, Sanger D (1988) Anxiogenic properties of beta-CCE and FG 7142: a review of promises and pitfalls. Psychopharmacology 94:452\u2013463","journal-title":"Psychopharmacology"},{"key":"1095_CR13","unstructured":"Wolters E, Scheltens P(eds) (1992) Mental dysfunction in Parkinson\u2019s disease. ICG, Dordrecht"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-002-1095-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-002-1095-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-002-1095-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T13:31:43Z","timestamp":1583415103000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-002-1095-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1007\/s00213-002-1095-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,1]]}}}